Monday, January 25, 2016

Athenex gets USFDA nod to conduct clinical trials for oral docetaxel

Athenex which has developed an oral version of anti-cancer drug docetaxel has been allowed to conduct clincial trials in the US. The oral version is supposed to offer the same efficacy but lower adverse effects and superior convenience compared to traditional / currently available IV version of docetaxel. An oral version would also reduce the overall cost of treatment as it would eliminate the need for a patient to visit the hospital. The basic technology in the development of the oral formulation is inlicensed from Hanmi pharmaceuticals.